
Please try another search
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
James G. McArthur | 61 | 2021 | President, CEO, Treasurer, Secretary & Director |
Laurie Bartlett Keating | 69 | 2021 | Independent Chair of the Board |
Heidi Henson | 57 | 2021 | Independent Director |
Charles Thornton | - | - | Scientific Advisory Board Member |
John W. Day | - | 2021 | Scientific Advisory Board Member |
Howard Mayer | 62 | 2023 | Independent Director |
Lisa Wyman | 47 | 2025 | Non-Executive Director |
Michael Gait | - | - | Founder & Scientific Advisory Board Member |
Mitchell H. Finer | 66 | 2025 | Independent Non-Executive Director |
Brenda Wong | - | - | Scientific Advisory Board Member |
Arthur M. Krieg | 68 | - | Scientific Advisory Board Member |
Habib Joseph Dable | 56 | 2022 | Independent Director |
Beth McNally | - | - | Scientific Advisory Board Member |
Joshua Resnick | 51 | 2020 | Independent Director |
Matthew Wood | - | - | Scientific Advisory Board Member |
Jonathan Watts | - | - | Scientific Advisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review